Clovis Oncology Inc (NASDAQ:CLVS) shares traded on 4.16% above secure line and closed at $24.8. The stock exchanged hands 2.78 Million shares versus average trading capacity of 3.3 Million shares. It has a market cap of $1.38 Billion.

Wall Street analysts are predicting that Clovis Oncology Inc (NASDAQ:CLVS) will report earnings per share of $-1.77 in their quarterly report. For the current quarter Clovis Oncology Inc (NASDAQ:CLVS) has high EPS estimates of $-1.57 in contradiction of low EPS estimates of $-1.93. However a year ago for the same quarter the company has reported $-1.04 EPS. Average estimation for the current quarter has been provided by 10 analysts.

Investors as well as the sell-side will be paying close attention to how the actual numbers compare with the estimates. Earnings surprises can have a huge impact on a company’s stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock’s price, but also to a gradual increase over time. Hence, it’s not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.

A large surprise factor in either direction typically can lead to a significant swing in the stock price in the hours and days after the report. Previously Clovis Oncology Inc (NASDAQ:CLVS) reported $-1.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $-1.6 by $-0.11 with surprise factor of -6.9%.

Clovis Oncology Inc (NASDAQ:CLVS) has average revenue estimates of $23.63 Million, compared to low analyst estimates of $22.5 Million and high estimates of $26 Million for the current quarter. A total number of 9 analysts provided estimations over revenues. For the current year the company’s revenue estimates are $88.9 Million compared to low analyst estimates of $87.6 Million and high estimates of $91 Million according to the prediction of 11 analysts.

Taking a broader look at the analyst consensus, according to 10 analysts Clovis Oncology Inc (NASDAQ:CLVS)’s price will reach at $27.1 during 52 weeks. Its minimum price target estimates has been figured out at $16 while the maximum price target forecast is established at $40.

On the other hand Clovis Oncology Inc (NASDAQ:CLVS) has Relative Strength Index (RSI 14) of 70.87 along with Average True Range (ATR 14) of 2.04. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock’s price movement. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls on all 14 days, and 100, if the price moves up on all the days) as suggested by J Welles Wilder. In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. The level of 50 represents neutral market momentum and corresponds with the center line in other oscillators such as MACD (Moving Average Convergence/Divergence). The average true range (ATR) is a measure of volatility introduced by Welles Wilder.

Consequently Clovis Oncology Inc (NASDAQ:CLVS)’s weekly and monthly volatility is 10.36%, 9.17% respectively.